Related Experiment Video
Updated: Apr 2, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
[Management of myelodysplastic syndromes]
Matthieu Duchmann1, Pierre Fenaux2, Thomas Cluzeau3
1Institut Gustave-Roussy, service d'hématologie, 94805 Paris, France.
Abstract:
Myelodysplastic syndromes are heterogeneous diseases whose molecular characteristics have only been identified in recent years. Better identification of prognostic factors, larger access to allogeneic stem cell transplantation and the advent of new drugs notably hypomethylating agents (azacitidine, decitabine) and lenalidomide have improved patient outcome.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Mitral Stenosis III: Medical Management
Cardiomyopathy V: Interprofessional Care

